Comprehensive antigen screening identifies Moraxella catarrhalis proteins that induce protection in a mouse pulmonary clearance model

Moraxella catarrhalis is one of the three most common causative bacterial pathogens of otitis media, however no effective vaccine against M. catarrhalis has been developed so far. To identify M. catarrhalis vaccine candidate antigens, we used carefully selected sera from children with otitis media a...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 8; no. 5; p. e64422
Main Authors Smidt, Margarita, Bättig, Patrick, Verhaegh, Suzanne J C, Niebisch, Axel, Hanner, Markus, Selak, Sanja, Schüler, Wolfgang, Morfeldt, Eva, Hellberg, Christel, Nagy, Eszter, Lundberg, Urban, Hays, John P, Meinke, Andreas, Henriques-Normark, Birgitta
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 09.05.2013
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Moraxella catarrhalis is one of the three most common causative bacterial pathogens of otitis media, however no effective vaccine against M. catarrhalis has been developed so far. To identify M. catarrhalis vaccine candidate antigens, we used carefully selected sera from children with otitis media and healthy individuals to screen small-fragment genomic libraries that are expressed to display frame-selected peptides on a bacterial cell surface. This ANTIGENome technology led to the identification of 214 antigens, 23 of which were selected by in vitro or in vivo studies for additional characterization. Eight of the 23 candidates were tested in a Moraxella mouse pulmonary clearance model, and 3 of these antigens induced significantly faster bacterial clearance compared to adjuvant or to the previously characterized antigen OmpCD. The most significant protection data were obtained with the antigen MCR_1416 (Msp22), which was further investigated for its biological function by in vitro studies suggesting that Msp22 is a heme binding protein. This study comprises one of the most exhaustive studies to identify potential vaccine candidate antigens against the bacterial pathogen M. catarrhalis.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Conceived and designed the experiments: MS PB SV AN MH SS EN UL JH AM BH-N. Performed the experiments: MS PB SV AN WS EM CH. Analyzed the data: MS PB SV AN MH SS WS EM CH EN UL JH AM BH-N. Contributed reagents/materials/analysis tools: AN MH SS WS UL JH AM BH-N. Wrote the paper: MS PB SV SS WS EN UL JH AM BH-N.
Current address: Eucodis Bioscience GmbH, Campus Vienna Biocenter 2, Vienna, Austria
Current address: Arsanis Biosciences GmbH, Vienna, Austria
Competing Interests: AN is an employee of Eucodis Bioscience GmbH. MH, WS, UL, and AM are employees of Intercell AG. EN is an employee of Arsanis Biosciences GmbH. There are no products in development or marketed products to declare. The following patent applications relating to the described data are pending: US-2012-0141487 published on 7 June 2012 and EP 2′435′063 published on 4 April 2011, both have the title Moraxella catarrhalis antigens. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0064422